Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146696 | 1.00 | RXFP1 (1.00) | RXFP1L3MBTL1TSHRMAPK1HSD17B10 | |
| SCHEMBL14832794 | 0.81 | RXFP1 (0.69) | RXFP1L3MBTL1TSHRMAPK1HSD17B10 | |
| SCHEMBL497285 | 0.79 | NPC1 (0.69) | RXFP1L3MBTL1TSHRSMN1; SMN2GABRA1 | |
| SCHEMBL497344 | 0.79 | RXFP1 (0.65) | RXFP1L3MBTL1TSHRSMN1; SMN2LMNA | |
| SCHEMBL30645154 | 0.79 | L3MBTL1 (0.65) | RXFP1L3MBTL1TSHRMAPK1HSD17B10 | |
| SCHEMBL30645159 | 0.79 | L3MBTL1 (0.65) | RXFP1L3MBTL1TSHRMAPK1HSD17B10 | |
| Dimethylamine SCHEMBL496581 | 0.78 | SMN1; SMN2 (0.66) | RXFP1L3MBTL1TSHRSMN1; SMN2GABRA1 | |
| SCHEMBL2830794 | 0.77 | RXFP1 (0.62) | RXFP1L3MBTL1TSHRSMN1; SMN2LMNA | |
| SCHEMBL5515985 | 0.75 | KAT2B (0.62) | RXFP1L3MBTL1SMN1; SMN2HTTMEN1 | |
| SCHEMBL496814 | 0.75 | MAPT (0.76) | RXFP1L3MBTL1TSHRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-4458358-A1 | PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY | Tietze Chemical Consulting UG (DE) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4404931-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| EP-4279074-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | RXFP1 2969/4885L3MBTL1 1588/4885TSHR 2032/4885 |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | RXFP1 357/4885L3MBTL1 3155/4885TSHR 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.